	Comparison of the effects of exercise-based interventions on cardiometabolic health and fatigue in men with prostate cancer receiving androgen deprivation therapy: A network meta-analysis. Asia Pac J Oncol Nurs Quan L, Zhang Y, Wu S, Hou S, Li K, Tian W, Wang W. PMID: 42022295 [PubMed]
	Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naÃ¯ve non-muscle invasive bladder cancer: Systematic review and meta-analysis. BJUI Compass Titus RS, Riveros C, Velasquez EL, Nguyen DD, Somawardana S, Singh A, Kaushik D, Sonpavde G, Zlotta A, Kulkarni G, Sridhar SS, Wallis CJD, Satkunasivam R. PMID: 42022227 [PubMed]
	Diagnostic and therapeutic challenges in intradiverticular bladder carcinoma: A case report. Urol Case Rep Manoj A, Chakraborty S, Kantha A, Pandey M. PMID: 42021970 [PubMed]
	Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study. Cancer Commun (Lond) Li H, Chen M, Huang R, Rong Q, Hao J, Zheng Q, Su Y, Shu D, Zhang Y, Yang W, Lei X, Cai Y, Xue C, An X, Shi Y. PMID: 42021969 [PubMed - indexed for MEDLINE]
	Correction: Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study. BMC Med Yu EY, Wesselius A, Mehrkanoon S, Goosens M, Brinkman M, van den Brandt P, Grant EJ, White E, Weiderpass E, Le Calvez-Kelm F, Gunter MJ, Huybrechts I, Riboli E, Tjonneland A, Masala G, Giles GG, Milne RL, Zeegers MP. PMID: 42021259 [PubMed - in process]
	First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study. Target Oncol Watanabe H, Nakane K, Nukaya T, Naiki T, Yasui T, Takahara K, Koie T, Inamoto T, Miyake H. PMID: 42020851 [PubMed - as supplied by publisher]
	[(68)Ga]Ga-NY104 PET/CT for the detection of clear cell renal cell carcinoma in presurgical patients with renal masses (NYCRPS): a prospective, single-centre, phase II study. Eur J Nucl Med Mol Imaging Yan X, Zheng G, Wang J, Liu M, Chen J, Xie Y, Fu C, Zhang Y, Zhu W, Huo L. PMID: 42020811 [PubMed - as supplied by publisher]
	Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients. Nat Commun Heumann P, Aguado-Barrera ME, Jandu HK, Azria D, Briers E, Bultijnck R, Chang-Claude J, Choudhury A, Dunning AM, Fachal L, Fuentes-Ríos O, Gómez-Caamaño A, Gutiérrez-Enríquez S, Kaaks R, Kerns SL, Lambrecht M, Romero JCR, Rosenstein BS, De Ruysscher D, Schmidt ME, Sperk E, Stobart H, Symonds RP, Veldeman L, Veldwijk MR, Ward T, Webb A, West CML, Rancati T, Rattay T, Vega A, REQUITE Consortium, Talbot CJ, Seibold P. PMID: 42020408 [PubMed - indexed for MEDLINE]
	Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. Eur Urol Oncol Vauchier C, Thibault C, Velev M, Becker O, Guillaume Z, Ashton E, Zaibet S, Berthou H, Courtinat F, Gervais C, Rochand A, Robbrecht D, Oudard S, Auclin E. PMID: 42020286 [PubMed - as supplied by publisher]
	Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-GuÃ©rin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. Eur Urol Lobo N, Contieri R, Mertens L, Kamat AM. PMID: 42020257 [PubMed - as supplied by publisher]
	Phase 1 Dose-Escalation Study of [(225)Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry. J Nucl Med Ling SW, Konijnenberg M, Segbers M, Hooijman E, Koolen S, de Blois E, De Jong LC, van Puffelen A, de Lussanet de la Sabloniere Q, Bruchertseifer F, Chilug EL, Morgenstern A, van der Veldt A, Brabander T. PMID: 42020144 [PubMed - as supplied by publisher]
	Prostate Cancer Screening in the MR Imaging Era: Evidence, Strategies, and Future Directions. Radiol Clin North Am Cochran RL, Harisinghani MG. PMID: 42020077 [PubMed - indexed for MEDLINE]
	Uncertainty-aware AI for tumor subtyping with histology and immunohistochemistry: A multi-center study in Renal Cell Carcinoma. Comput Methods Programs Biomed Hosseini SMM, Hannetel P, Di Cataldo S, Descombes X, Sibony M, Decaussin M, Ponzio F, Ambrosetti D. PMID: 42019354 [PubMed - as supplied by publisher]
	Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer. Eur J Cancer Develtere D, Tsantoulis P, Olivier T. PMID: 42019224 [PubMed - as supplied by publisher]
	Outcomes of immune-checkpoint inhibitor rechallenge in metastatic clear-cell renal cell carcinoma: results from a global real-world evidence study. ESMO Open Cigliola A, Maiorano BA, Rossari F, Tateo V, Mercinelli C, Dizman N, Colecchia M, De Cobelli F, Larcher A, Rosiello G, Briganti A, Montorsi F, Capitanio U, Spiess PE, Agarwal N, Pal SK, Necchi A. PMID: 42019087 [PubMed - as supplied by publisher]
	Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development. Hepatol Res Lim J, Kim SH, Song MJ. PMID: 42018764 [PubMed - as supplied by publisher]
	Diagnostic Approaches to Adult Cystic Nephroma: Insights From Two Cases. Am J Case Rep Bosoteanu M, Vod, Or, Nurla LA, Ciufu N. PMID: 42018497 [PubMed - indexed for MEDLINE]
	TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies. Mol Cancer Ther Hoshi-Kadonosawa Y, Reinhold WC, Taniyama D, Inoue Y, Luna A, Kumar S, Sun NY, Kim YS, Yin JJ, Roper N, Sowalsky AG, Figg WD, Takebe N, Pommier Y. PMID: 42018155 [PubMed - as supplied by publisher]
	CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer. Cancer Immunol Immunother Furriel F, Laranjeira P, Pereira M, Silva S, Silva I, Fontinha G, Sousa V, Gomes C, Parada B, Paiva A. PMID: 42018002 [PubMed - indexed for MEDLINE]
	Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer. Int J Cancer Han Z, Yi X, Tang Y, Li X, Liao D, Xu H, Zheng X, Ai J. PMID: 42017392 [PubMed - as supplied by publisher]

Articles 1 - 20 / 177675

Page 1 of 8884



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy